Agreement to License almaKnowledgeServer (AKS) as Part of Joint Research Project
News Sep 16, 2005
bioalma has announced that EMBL has licensed almaKnowledgeServer (AKS) for an initial period of three years.
Under this agreement, researchers based at EMBL headquarters in Heidelberg, as well as those based at outstations located in Germany, United Kingdom, Italy and France, will have access to the system as part of their daily research activities.
bioalma and EMBL are also pleased to announce a joint development project to tailor almaKnowledgeServer (AKS) features to the needs of the EMBL organization.
Juan Carlos del Castillo, CEO of bioalma, said, "This is exactly the kind of collaboration we are actively seeking as the worldwide reputation of EMBL as a centre of research excellence."
Christian Blaschke, CSO, Text Mining at bioalma, has added, "With EMBL's enormous expertise at hand, AKS will extend its coverage of chemical information detected in the literature.”
“This move increases remarkably bioalma's solutions competitiveness in fields like toxicology and metabolomics."
"Text mining already plays an important role in life sciences,” says Dr. Reinhard Schneider, who leads the Data Integration and Knowledge Management Team at the EMBL.
“We expect that the impact of text mining will increase over the next few years and that the application of the underlying technology will move away from the experts' desks to become a daily used tool by life science researchers,"
"With bioalma's AKS we have a system at hand which is from day one a valuable tool for our researchers as well as a great research vehicle to allow us to explore the application of text mining technologies as part of automatic analysis workflows."
A skin swab test for Parkinson's has become a real possibility, after mass spectrometry was used to detect altered levels of specific compounds on the skin of people with the condition. The research is a result of the incredible ability of one woman to detect a unique odor on the skin of people with Parkinson's disease. These findings open the door to a non-invasive screening test.READ MORE